Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
克里唑蒂尼
阿列克替尼
医学
间变性淋巴瘤激酶
碱性抑制剂
肺癌
内科学
肿瘤科
恶性胸腔积液
作者
George Gourzoulidis,Oresteia Zisimopoulou,Andrianos Liavas,C. Tzanetakos
Lorlatinib provides substantial clinical benefit and appears to be a cost - effective treatment option compared to 1st and 2nd generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.
PDF的下载单位、IP信息已删除
(2025-6-4)
毛豆
Kao
GingerF
yjh123
NYX
学术文献互助
Copyright
Criminology34
Oracle
东方元语
Nexus
hui_zhou
BigTong
keven
phdbio
pluto
arniu2008
平常千万
77
lizishu
皖公网安备34019202002308
